24 January 2021>: Clinical Research
Elevated Plasma Angiopoietinlike Protein 5 (ANGPTL5) Is More Positively Associated with Glucose Metabolism Disorders in Patients with Metabolic Syndrome
Chang Liu 123ABCD* , Xin Yi 123AEG* , Yongnan Lyu 123CF , Wei Ren 4CD , Yi Zhou 123BF , Gaoke Feng 123E , Weiguo Wan 123B , Xue-jun Jiang 123AEG*DOI: 10.12659/MSM.929626
Med Sci Monit 2021; 27:e929626
Table 1 Demographic and clinical characteristics of subjects included.
Variables | non-MS (n=70) | MS (n=69) | Total (n=139) | P value |
---|---|---|---|---|
Age (years) | 54.96±17.04 | 60.14±12.91 | 57.52±15.30 | 0.045 |
Male (%) | 48.57% | 53.62% | 51.08% | 0.551 |
Smoking (%) | 51.43% | 49.28% | 50.36% | 0.800 |
Family history | ||||
Diabetes (%) | 15.71% | 40.58% | 28.06% | 0.002 |
Hypertension (%) | 65.71% | 62.32% | 64.03% | 0.677 |
Waist circumference (cm) | ||||
Men | 84.38±2.85 | 94.35±3.52 | 89.58±5.94 | |
Women | 81.22±2.34 | 89.56±4.07 | 85.15±5.30 | |
WHR | 0.82±0.05 | 0.98±0.08 | 0.90±0.10 | |
BMI (kg/m) | 21.86±1.22 | 27.04±2.75 | 24.43±3.35 | |
SBP (mmHg) | 127.47±11.81 | 141.91±20.22 | 134.64±10.27 | |
DBP (mmHg) | 77.71±10.26 | 75.14±10.20 | 76.44±10.27 | 0.141 |
FPG (mmol/L) | 5.10 (5.00–5.30) | 6.80 (6.25–7.65) | 5.50 (5.10–6.80) | |
FINS (μU/ml) | 10.10 (9.08–11.60) | 11.90 (10.45–13.55) | 10.80 (9.40–12.60) | |
HbA1c (%) | 5.30 (5.10–5.50) | 5.90 (5.70–6.90) | 5.60 (5.30–5.90) | |
TC (mmol/L) | 4.02±0.63 | 4.82±0.90 | 4.42±0.87 | |
TG (mmol/L) | 1.02 (0.78–1.41) | 1.77 (1.47–2.35) | 1.43 (0.96–1.81) | |
HDL-C (mmol/L) | 1.32±0.25 | 1.20±0.26 | 1.26±0.26 | 0.009 |
LDL-C (mmol/L) | 2.19±0.51 | 3.11±0.78 | 2.64±0.80 | |
hs-CRP (mg/L) | 2.80 (1.85–3.63) | 3.90 (1.30–7.78) | 3.15 (1.50–4.43) | 0.006 |
BUN (mmol/L) | 4.92 (3.84–5.64) | 5.05 (4.32–6.05) | 4.99 (3.99±5.90) | 0.128 |
CREA (μmol/L) | 66.50 (55.00–81.25) | 69.00 (54.50–80.00) | 68.00 (55.00–81.00) | 0.893 |
URIC (μmol/L) | 264.43±59.78 | 318.52±72.86 | 291.28±71.69 | |
TBIL (μmol/L) | 13.54±5.48 | 14.13±5.27 | 13.83±5.36 | 0.519 |
DBIL (μmol/L) | 4.71±2.26 | 4.27±1.95 | 4.49±2.12 | 0.251 |
IBIL (μmol/L) | 8.80±3.52 | 9.85±3.69 | 9.32±3.63 | 0.088 |
AST (U/L) | 15.00 (12.00–20.25) | 16.00 (13.00–20.00) | 16.00 (12.00–20.00) | 0.485 |
ALT (U/L) | 14.00 (10.00–20.00) | 15.00 (11.00–19.00) | 15.00 (10.00–20.00) | 0.848 |
GGT (U/L) | 19.50 (12.75–33.50) | 20.00 (16.00–29.50) | 20.00 (14.00–33.00) | 0.537 |
HOMA-IR | 2.23 (2.04–2.67) | 3.56 (3.05–4.53) | 2.88 (2.23–3.58) | |
HOMA-β | 121.91 (107.22–150.61) | 70.77 (50.95–89.29) | 103.33 (70.77–128.00) | |
ANGPTL5 (pg/ml) | 184.70±68.59 | 321.21±79.30 | 252.47±100.71 | |
Data are presented as the mean±SD and median (interquartile range). Differences between groups were analyzed by the independent test, chi-square test, or Mann-Whitney test. MS – metabolic syndrome; WHR – waist-hip ratio; BMI – body mass index; SBP – systolic blood pressure; DBP – diastolic blood pressure; FPG – fasting plasma glucose; FINS – fasting insulin; HbA1c – glycated hemoglobin; TC – total cholesterol; TG – triglyceride; HDL-C – high-density lipoprotein cholesterol; LDL-C – low-density lipoprotein cholesterol; hs-CRP – high-sensitivity C-reactive protein; BUN – blood urea nitrogen; CREA – creatinine; URIC – uric acid; TBIL – total bilirubin; DBIL – direct bilirubin; IBIL – indirect bilirubin; AST – aspartate aminotransferase; ALT – alanine aminotransferase; GGT – glutamine transpeptidase; HOMA-IR – homeostasis model assessment of insulin resistance; HOMA-β – HOMA of β-cell function; ANGPTL5 – angiopoietinlike protein 5. |